1. Hauptnavigation
  2. Navigation des Hauptbereiches
  3. Inhalt der Seite

Division of Translational Oncology

Prof. Dr. Christof von Kalle

The Department of Translational Oncology (Christof von Kalle) coordinates all major aspects of NCT´s further development and translational oncology at DKFZ. As part of the translational cancer research process, the department is deeply involved in the clinical activities of NCT and contributes to trial development, with a special focus on molecular diagnosis and therapy. 6 Physician scientists of the department participate in patient care in outpatient clinics, tumor boards and clinical standard conferences of the center, and support diagnostic and therapeutic translation from DKFZ and HUMS into innovative clinical trials.

The research program of the department focuses on Applied Stem Cell Research (Hanno Glimm), Molecular and Gene Therapy (Manfred Schmidt), Molecular and Cellular Oncology (Stefan Fröhling), Functional Genomics (Claudia Scholl), Molecular Therapy in Hematology and Oncology (Thorsten Zenz), and Virotherapy (Guy Ungerechts).

Towards personalized oncology, the department coordinates the development of the NCT Precision Oncology Program (NCT POP). NCT POP focuses all translational activities towards individualized cancer medicine, including patient-oriented strategies in genomics, proteomics, immunology, radiooncology, prevention, and early clinical development. The department has implemented the center-wide NCT MASTER (Molecularly Aided Stratification for Tumor Eradication) umbrella protocol. NCT MASTER provides a clinical implementation workflow for high-throughput diagnostics: quality-assured sample acquisition; histopathological evaluation; quality-managed analyte extraction; NGS and other “omics” technologies; bioinformatic processing; GLP-certified validation of variants; and clinical evaluation by a molecular tumor board. NCT MASTER makes it possible to perform and evaluate molecular diagnostics on materials from all consenting NCT patients, with the explicit purpose of stratifying each patient for the best treatment or trial strategy.

Selected Publications

Gabriel, R, von Kalle, C, Schmidt, M. Mapping the precision of genome editing. Nat Biotechnol 2015; 33(2):150-152.

Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 2012; 366(21), 2038-40

Dieter SM, Ball CR, Hoffmann CM, Nowrouzi A, Herbst F, Zavidij O, Abel U, Arens A, Weichert W, Brand K, Koch M, Weitz J, Schmidt M, von Kalle C, Glimm H. Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell 2011; 9(4), 357-65

Gabriel R, Lombardo A, Arens A, Miller JC , Genovese P, Kaeppel C, Nowrouzi A, Bartholomae CC, Wang J, Friedman G, Holmes MC, Gregory PD, Glimm H, Schmidt M, Naldini L, von Kalle C. An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nature Biotech 2011; 29(9), 816-23

last update: 05/04/2016 back to top